Gunda V, Ghosh C, Hu J, Zhang L, et al. Combination BRAFV600E inhibition with the multitargeting tyrosine kinase inhibitor axitinib shows additive anticancer activity in BRAFV600E-mutant anaplastic thyroid cancer. Thyroid 2023 Sep 7. doi: 10.1089/thy.2023.0201.
PMID: 37675898